Sebastian Pieperhoff

Affiliations
  • Novo Nordisk Pharma GmbH, Mainz, Germany.

Publications (1)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Avec: Markus Menzen , Tina Landsvig Berentzen , Andrei-Mircea Catarig , Sebastian Pieperhoff , Jörg Simon , Stephan Jacob

Réseau de co-auteurs

Markus Menzen 1 collaboration
Tina Landsvig Berentzen 1 collaboration
Andrei-Mircea Catarig 1 collaboration
Jörg Simon 1 collaboration
Stephan Jacob 1 collaboration